Neuroblastoma Drug Combo Extends Survival in Models

A Promising Shift in High-Risk Neuroblastoma Care

New research reveals how a drug combination in neuroblastoma may help children with relapsed disease, a group for whom treatment options remain extremely limited. 

Neuroblastoma remains the most common extracranial solid tumor in children, and recurrence continues to be a major challenge in pediatric oncology. Researchers at the Garvan Institute of Medical Research have identified a therapy pairing that bypasses the tumor’s cellular defenses, offering renewed hope for cases resistant to standard chemotherapy.

Explore All Oncology CME/CE Conferences and Online Courses

Why Current Treatments Fail, and How Resistance Develops

High-risk neuroblastoma frequently becomes resistant to therapy. A key mechanism behind this failure is tied to the JNK pathway, a cellular switch required for conventional chemotherapy-induced apoptosis.

In tumor samples analyzed before and after relapse, researchers found that the JNK pathway often becomes non-functional, leaving cancer cells “immune” to standard treatment pathways. This resistance contributes to poor outcomes, with recurrent high-risk disease remaining one of the most difficult pediatric cancers to treat.

Identifying Agents That Bypass Blocked Cell-Death Pathways

To overcome this resistance, investigators screened FDA-approved agents already holding pediatric safety data. One drug stood out: romidepsin, currently used for certain lymphomas. The compound triggered cancer cell death even when the JNK pathway was inactive, making it a promising candidate for overcoming resistant neuroblastoma biology.

In animal models conducted in partnership with the Children’s Cancer Institute, romidepsin combined with standard chemotherapy significantly slowed tumor growth and extended survival. Remarkably, lower chemotherapy doses paired with romidepsin matched the effectiveness of higher standard doses alone, suggesting the potential for reduced toxicity in future pediatric applications.

Implications for Pediatric Oncology and Future Care

Because romidepsin already has established safety data, its transition into neuroblastoma clinical research may be faster than a new investigational drug. For oncologists and pediatric specialists, these findings highlight a feasible strategy to target apoptosis through alternative signaling routes, critical for children whose cancers no longer respond to frontline regimens.

Further studies are now focused on optimizing the regimen, evaluating dosing schedules, and ensuring safety before advancing to human trials.

What This Means for Clinical Practice & Research

This emerging drug combination in neuroblastoma provides a promising direction for improving outcomes in relapsed and treatment-resistant disease. Pediatric oncologists, oncology nurses, and clinicians involved in multidisciplinary cancer care may soon see new therapeutic approaches that address resistance at the molecular level.

Stay informed on similar oncology breakthroughs and continuing education opportunities at eMedEvents.

Source:

Garvan Institute of Medical Research